Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aegera Therapeutics and The Leukemia & Lymphoma Society have executed an agreement for $3.3 million to support an international Phase I/II clinical trial.
Subscribe to our email newsletter
The trial is for Aegera’s AEG35156, a targeted therapy for blood cancer patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. The clinical trials will take place in Canada and the US.
The agreement marks the first clinical trial announced under the Leukemia & Lymphoma Society’s (LLS) therapy acceleration program, a program designed to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers.
Louis DeGennaro, chief scientific officer of LLS, said: “Our goal is to bring new therapies to patients. The partnership with Aegera accelerates the clinical testing of a novel blood cancer therapy and brings us closer to that goal.”